RECRUITING

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study. Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB).

Official Title

Correlation of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging and Tumor Histopathology in Patients With Infiltrating Gliomas

Quick Facts

Study Start:2020-08-11
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04772456

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * • Patients with a new brain lesion interpreted as suspected infiltrating gliomas including but not limited to (diffuse astrocytoma WHO grade 2; oligodendroglioma WHO grade 2 and 3; anaplastic astrocytoma WHO grade 3; astrocytoma WHO grade 4), OR, patients with prior history of infiltrating glioma scheduled for surgery for tumor biopsy or resection.
  2. * Ages 18-80, including male and female
  3. * Suitable to undergo contrast-enhanced MRI
  4. * Negative serum pregnancy test
  1. * Inability to undergo MRI scan
  2. * Inability to receive IV contrast secondary to severe reaction or renal insufficiency.

Contacts and Locations

Study Contact

Rosy Njonkou Tchoquessi
CONTACT
4107066445
rnjonkou@som.umaryland.edu

Principal Investigator

Dirk Mayer, Dr. rer. nat
PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore

Study Locations (Sites)

Rosy Njonkou Tchoquessi
Baltimore, Maryland, 21201
United States

Collaborators and Investigators

Sponsor: University of Maryland, Baltimore

  • Dirk Mayer, Dr. rer. nat, PRINCIPAL_INVESTIGATOR, University of Maryland, Baltimore

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-08-11
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2020-08-11
Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Glioma